References
- Centers for Disease Control and PreventionNational Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United StatesAtlanta, GAU.S. Department of Health and Human Services2014
- American Diabetes AssociationEconomic costs of diabetes in the U.S. in 2012Diabetes Care20133641033104623468086
- ChamberlainJJRhinehartASShaeferCFJrNeumanADiagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetesAnn Intern Med2016164854255226928912
- GarberAJAbrahamsonMJBarzilayJIAACE/ACE comprehensive diabetes management algorithm 2015Endocr Pract201521443844725877012
- BennettWLWilsonLMBolenSMaruthurNAgency for Healthcare Research and QualityOral diabetes medications for adults with type 2 diabetes: an update2011 Report No.: 11-EHC038-EF
- INVOKANA® (Canagliflozin) [Package Insert]Titusville, NJJanssen Pharmaceuticals, Inc2015
- StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
- PolidoriDShaSMudaliarSCanagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled studyDiabetes Care20133682154216123412078
- CefaluWLeiterLYoonKEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
- SchernthanerGGrossJRosenstockJCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylureaDiabetes Care20133692508251523564919
- LefebvrePPilonDRobitailleM-NReal-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based studyCurr Med Res Opin Res Opin201632611511159
- ThayerSChowWKorrerSAguilarRReal-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitorsCurr Med Res Opin20163261087109626938635
- ChowWBuysmanERupnowMFTAguilarRHenkHJCanagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care settingCurr Med Res Opin20163211322
- BuysmanEKChowWHenkHJRupnowMFTCharacteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysisBMC Endocr Disord20151516726527413
- NislySAKolanczykDMWaltonAMCanagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetesAm J Heal Pharm2013704311319
- BerwickDMNolanTWWhittingtonJThe triple aim: care, health, and costHealth Aff2008273759769
- BattiseDEfficacy and safety of canagliflozin as add-on therapy to metformin in type 2 diabetesClin Diabetes2014322818626130867
- LeiterLYoonKAriasPanagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks vs glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 studyDiabetes Care201538335536425205142
- Lavalle-GonzálezFJJanuszewiczADavidsonJEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia201356122582259224026211
- NardolilloAKaneMPBuschRSWatskyJHamiltonRAA clinical perspective of canagliflozin in the management of type 2 diabetes mellitusClin Med Insights Endocrinol Diabetes20147253025288892
- TrainaSGuthrieRSleeAThe impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetesPostgrad Med20141263715